{"entity":{"id":"nature-communications","kind":"journal","name":"Nature Communications","aka":["Nat Commun"],"tldr":"Springer Nature's large fully open-access multidisciplinary journal, carrying a high volume of cancer genomics, immunology, AI and translational papers.","summary":"Nature Communications (Nat Commun) is Springer Nature's large, fully open-access multidisciplinary journal, founded in 2010, publishing under CC BY licences with peer-review files often published alongside the article. It publishes thousands of articles a year across science, and in cancer it is a major venue for genomic and single-cell studies, immunology, AI and computational methods, and secondary analyses of trial biospecimens. Its readers are researchers across disciplines who want open-access primary research. Within OnCo it is linked from the biographies of Woong-Yang Park, Robert Gatenby, Giovanni Blandino and Viktor Adalsteinsson, and a reader would use it for the high volume of cancer genomics and translational papers it carries.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/ncomms/","issn":"2041-1723","scope":"general science","access":"open-access","founded":2010,"matchNames":["Nature Communications","Nat Commun"]},"route":"/journals/nature-communications/","neighbours":{"paper":[{"id":"paper-yamazaki-nat-commun","kind":"paper","name":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","route":"/key-papers/paper-yamazaki-nat-commun/"},{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/"},{"id":"paper-sausen-ctdna-pancreatic-resection-nat-commun-2015","kind":"paper","name":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","route":"/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/"},{"id":"paper-menden-nat-commun","kind":"paper","name":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","route":"/key-papers/paper-menden-nat-commun/"},{"id":"paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014","kind":"paper","name":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","route":"/key-papers/paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014/"},{"id":"paper-santosh-kesari-nat-commun-2026","kind":"paper","name":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","route":"/key-papers/paper-santosh-kesari-nat-commun-2026/"},{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/"},{"id":"paper-de-groot-nat-commun","kind":"paper","name":"Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial","route":"/key-papers/paper-de-groot-nat-commun/"},{"id":"paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021","kind":"paper","name":"Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer","route":"/key-papers/paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021/"},{"id":"paper-noe-cyst-malignant-progression-genomics-nat-commun-2020","kind":"paper","name":"Genomic characterization of malignant progression in neoplastic pancreatic cysts","route":"/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/"},{"id":"paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017","kind":"paper","name":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","route":"/key-papers/paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017/"},{"id":"paper-pandey-gallbladder-elf3-nat-commun-2020","kind":"paper","name":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","route":"/key-papers/paper-pandey-gallbladder-elf3-nat-commun-2020/"},{"id":"paper-zhang-nat-commun","kind":"paper","name":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","route":"/key-papers/paper-zhang-nat-commun/"},{"id":"paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","kind":"paper","name":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","route":"/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/"},{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/"},{"id":"paper-koelsche-nat-commun","kind":"paper","name":"Sarcoma classification by DNA methylation profiling","route":"/key-papers/paper-koelsche-nat-commun/"},{"id":"paper-ma-nat-commun","kind":"paper","name":"Segment anything in medical images","route":"/key-papers/paper-ma-nat-commun/"},{"id":"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019","kind":"paper","name":"The molecular origin and taxonomy of mucinous ovarian carcinoma","route":"/key-papers/paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019/"},{"id":"paper-mountaineer-nat-commun-2026-update","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","route":"/key-papers/paper-mountaineer-nat-commun-2026-update/"},{"id":"paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","kind":"paper","name":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","route":"/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/"}],"person":[{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/"},{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/"},{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","route":"/people/magdolna-dank/"},{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/"},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/"},{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","route":"/people/viktor-adalsteinsson/"},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/"},{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/"}]}}